AMA Establishes CPT Codes For Minimally Invasive ESD Procedure

(MENAFN- PR Newswire) The dedicated CPT codes for the ESD procedure will allow for more widespread clinical adoption of the procedure and remove barriers to patient access. This will be facilitated through a standardized and streamlined reimbursement process for health care providers and payers.

"We applaud the AMA's decision to establish these new CPT codes, which will help more patients and physicians access the ESD procedure for the minimally invasive treatment of pervasive GI diseases and disorders," said Paul Skodny, Senior Director for Health Economics and Market Access at Olympus Corporation. "This positive result is the culmination of much hard work and broad support for creating this reimbursement pathway."

ESD is a minimally invasive, organ-sparing endoscopic procedure used to diagnose and treat cancerous and pre-cancerous neoplasms of the gastrointestinal (GI) tract. Rather than surgically removing whole sections of the GI tract through incisions on the skin, physicians remove tumors through natural orifices, via an endoscope, in one piece. This technique enables accurate staging of these lesions by pathologists, leading to less recurrence rates than other endoscopic methods.ⁱⁱ Without large incisions or having sections of organs removed, patients experience less pain, faster healing and may not suffer the potential consequences of segmental resections.^iii,iv

"We are thrilled to reach this significant reimbursement milestone for the ESD procedure," said Mike Callaghan, General Manager for EndoTherapy at Olympus Corporation. "Olympus has been at the forefront of developing ESD solutions since the procedure was first pioneered by Japanese clinicians working collaboratively with Olympus. This decision by the AMA will facilitate broader adoption of this procedure in the U.S., and it will enhance patient care by providing more patients with access to an advanced and novel treatment option."

Visit the Olympus Americas ESD web page for more information about the ESD procedure: href="" rel="nofollow" olympusamerica/endoscopic-submucosal-dissectio

About Olympus
At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states.

For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.

Olympus Corporation of the Americas, a wholly owned subsidiary of Olympus Corporation, is headquartered in Center Valley, Pennsylvania, USA, and employs more than 4,500 employees throughout locations in North and South America. For more information, visit href="" rel="nofollow" olympusameric .

ⁱ Summary of Panel AMA-ASSN. Updated May 16, 2025. Accessed May 20, 2025. .
ⁱⁱ Fukami, N. Endoscopic Submucosal Dissection in the Esophagus: Indications, Techniques, and Outcomes, Gastrointestinal Endoscopy Clinics of North America. 2023;33(1);55-66. 1016/j.2022.09.003.
ⁱⁱⁱ Abdelfatah MM, Barakat M, Ahmad D, Ibrahim M, Ahmed Y, Kurdi Y, Grimm IS, Othman MO. Long-term outcomes of endoscopic submucosal dissection versus surgery in early gastric cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019;31(4):418-424. Doi:10.1097/MEG.0000000000001352. PMID: 30694909
^iv Qian M, Sheng Y, Wu M, Wang S, Zhang K. Comparison between Endoscopic Submucosal Dissection and Surgery in Patients with Early Gastric Cancer. Cancers. 2022; 14(15):3603.

SOURCE Olympus Corporation of the Americas

MENAFN22052025003732001241ID1109584526